SAN DIEGO, CA--(Marketwired - Mar 17, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, has announced today the availability of its male fertility supplement Androferti® in the U.S.
The launch was preceded by the formation of a top Clinical Advisory Board formed by the top in-vitro fertilization ("IVF") specialists in the U.S. The Clinical Advisory was led by Dr. Fady Sharara, one of the top infertility doctors in the U.S. who was voted one of the Top Doctors in Infertility by the Washington Post Magazine, Washingtonian Magazine, and Northern Virginia Magazine, among others. "Androferti® is step forward in the fight against male infertility and a great clinically proven supplement to help increase the success of conception of patients in the U.S.," said Dr. Sharara.
"We are very excited to launch such a strong and clinically proven product in the U.S. to help patients in their quest for a higher conception success," said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus.
"According to reports by IBIS World in August 2014, the fertility market is estimated to be around $2 billion with a 2.5% yearly increase. With only 682 In-Vitro Fertility clinics in the U.S., we should be able to reach most of these clinics within a relatively short period of time. The Company anticipates millions of dollars in sales annually upon and if reaching full market penetration," continued Dr. Damaj.
Androferti® will be available directly to IVF clinics and online at www.myandroferti.com at a price of $85 per box, which is sufficient for a one month supply. For optimal results from the published clinical trials optimal results of Androferti® are observed with 3 months of continuous use.
Androferti®, has been shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhance spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperm ("REM")).
The Company believes that Androferti® is the only product clinically proven to increase the Sperm Quality and enhance Spermatozoa Quality as compared to other products where the claims are based primarily on an ingredient used in the products.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to: www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone; www.getbeyondhuman.com; www.trybeyondhuman.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals, whether we and our distributors will continue to successfully market and sell our products such as Androferti® in the U.S. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.